Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology.
暂无分享,去创建一个
He Lian | Jin Sun | Zhonggui He | Jin Sun | Le Sun | Zhonggui He | He Lian | Chunnuan Wu | Xiaoyu Ai | Chunnuan Wu | Le Sun | Yajun Yang | Congcong Ren | Xiaoyu Ai | Congcong Ren | Yajun Yang
[1] Lawrence X. Yu,et al. Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development , 2011, The AAPS Journal.
[2] Thierry Lavé,et al. Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.
[3] T. Makino,et al. Stabilization of a new antiulcer drug (Lansoprazole) in the solid dosage forms , 1992 .
[4] F. Vrečer,et al. The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: an in vitro/in vivo correlation. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[5] Christos Reppas,et al. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[6] Xinyuan Zhang,et al. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. , 2011, International journal of pharmaceutics.
[7] F. Vrečer,et al. Preformulation Investigation of the Novel Proton Pump Inhibitor Lansoprazole , 2000, Drug development and industrial pharmacy.
[8] Arik Dahan,et al. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. , 2012, Molecular pharmaceutics.
[9] G L Amidon,et al. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.
[10] K. Higaki,et al. Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[11] G. Amidon,et al. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. , 2011, Molecular pharmaceutics.
[12] L. Schanker. On the mechanism of absorption of drugs from the gastrointestinal tract. , 1960, Journal of medicinal and pharmaceutical chemistry.
[13] J. Horn,et al. The proton-pump inhibitors: similarities and differences. , 2000, Clinical therapeutics.
[14] A. Dahan,et al. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. , 2012, Molecular pharmaceutics.
[15] Neil Parrott,et al. Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.
[16] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[17] Siling Wang,et al. Relationship between dissolution and bioavailability for nimodipine colloidal dispersions: the critical size in improving bioavailability. , 2012, International journal of pharmaceutics.
[18] Gordon L. Amidon,et al. Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model , 1993, Pharmaceutical Research.
[19] Kazuhide Yamamoto,et al. Proton Pump Inhibitor Dose-Related Healing Rate of Artificial Ulcers after Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial , 2011, Digestion.
[20] L. Schanker. Absorption of drugs from the rat colon. , 1959, The Journal of pharmacology and experimental therapeutics.
[21] Martin Kuentz,et al. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[22] M. Odomi,et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[23] L. A. Fenu,et al. The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools , 2007, Drug Metabolism and Disposition.
[24] A. Noyes,et al. The rate of solution of solid substances in their own solutions , 1897 .
[25] H. Lennernäs,et al. Oral Drug Absorption: Prediction and Assessment , 2000 .
[26] Jennifer B Dressman,et al. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[27] Filippos Kesisoglou,et al. Understanding the Effect of API Properties on Bioavailability Through Absorption Modeling , 2008, The AAPS Journal.
[28] Gordon L Amidon,et al. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. , 2010, Journal of pharmaceutical sciences.
[29] Mitra Mosharraf,et al. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs , 1995 .
[30] L. A. Fenu,et al. Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.
[31] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[32] Thierry Lavé,et al. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[33] R. J. Hintz,et al. The effect of particle size distribution on dissolution rate and oral absorption , 1989 .
[34] Raimar Löbenberg,et al. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[35] P J Sinko,et al. Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.